Assay for human breast cancer

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424 858, 436501, 436518, 436536, 436548, 436813, 530387, G01N 33577

Patent

active

048031690

ABSTRACT:
Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.

REFERENCES:
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4753894 (1988-06-01), Frankel et al.
Frankel et al "Tissue Distribution of Breast Cancer-Associated Antigens Defined by Monoclonal Antibodies", J. Biol. Res. Mod. 4:273-286 1985.
Ceriani et al, PNAS (1982) 79:5420-5424.
Burchell, J. et al, Int J Cancer (1984) 34:763-768.
Hayes, D. F., J Clin Invest (1985) 75:1671-1678.
Roberto L. Ceriani et al. (1983) Somatic Cell Genetics, 9:415-427.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Assay for human breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Assay for human breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for human breast cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1084697

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.